MX2017005042A - Formas de dosificacion oral de magnesio de liberacion controlada, de alta carga y metodos para elaborar y utilizar las mismas. - Google Patents
Formas de dosificacion oral de magnesio de liberacion controlada, de alta carga y metodos para elaborar y utilizar las mismas.Info
- Publication number
- MX2017005042A MX2017005042A MX2017005042A MX2017005042A MX2017005042A MX 2017005042 A MX2017005042 A MX 2017005042A MX 2017005042 A MX2017005042 A MX 2017005042A MX 2017005042 A MX2017005042 A MX 2017005042A MX 2017005042 A MX2017005042 A MX 2017005042A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- dosage forms
- magnesium
- controlled
- oral dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen formas de dosificación de alta carga, de liberación controlada para administración oral de sales de magnesio. Por ejemplo, una forma de dosificación oral puede comprender desde aproximadamente 80% hasta aproximadamente 95% de lactato de magnesio y uno o más componentes. Como otro ejemplo, una forma de dosificación oral puede comprender por lo menos aproximadamente 50% de sal de magnesio y exhibe un perfil de disolución de liberación controlada. También se describen métodos para elaborar formas de dosificación de liberación controlada para administración oral de una cantidad terapéuticamente efectiva de sal de magnesio a un mamífero. También se describen métodos para tratar un trastorno caracterizado por deficiencia de magnesio y métodos para prevenir o aliviar bajos niveles de magnesio.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/132,461 US9707253B2 (en) | 2008-05-19 | 2016-04-19 | High-loading, controlled-release magnesium oral dosage forms and methods for making and using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017005042A true MX2017005042A (es) | 2018-08-20 |
Family
ID=58578872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017005042A MX2017005042A (es) | 2016-04-19 | 2017-04-18 | Formas de dosificacion oral de magnesio de liberacion controlada, de alta carga y metodos para elaborar y utilizar las mismas. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3243507A1 (es) |
| JP (1) | JP2017214352A (es) |
| KR (1) | KR20170119651A (es) |
| AR (1) | AR108235A1 (es) |
| AU (1) | AU2017202534B1 (es) |
| CA (1) | CA2964581C (es) |
| CL (1) | CL2017000957A1 (es) |
| MX (1) | MX2017005042A (es) |
| MY (1) | MY185460A (es) |
| RU (1) | RU2017113518A (es) |
| SG (1) | SG10201703206TA (es) |
| ZA (1) | ZA201702773B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4212149A1 (en) * | 2022-01-18 | 2023-07-19 | Rijksuniversiteit Groningen | Oral dosage forms of acid-labile salt and methods and uses related thereto |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5002774A (en) * | 1989-06-08 | 1991-03-26 | Erbamont, Inc. | Sustained release pharmaceutical tablet |
| CN102098921A (zh) * | 2008-05-19 | 2011-06-15 | 温顿制药有限公司 | 高载量、控释镁口服制剂及其制备和使用方法 |
-
2017
- 2017-04-17 JP JP2017081314A patent/JP2017214352A/ja active Pending
- 2017-04-17 MY MYPI2017000564A patent/MY185460A/en unknown
- 2017-04-18 EP EP17166926.0A patent/EP3243507A1/en not_active Ceased
- 2017-04-18 CA CA2964581A patent/CA2964581C/en active Active
- 2017-04-18 AU AU2017202534A patent/AU2017202534B1/en active Active
- 2017-04-18 MX MX2017005042A patent/MX2017005042A/es active IP Right Grant
- 2017-04-18 CL CL2017000957A patent/CL2017000957A1/es unknown
- 2017-04-19 ZA ZA2017/02773A patent/ZA201702773B/en unknown
- 2017-04-19 RU RU2017113518A patent/RU2017113518A/ru not_active Application Discontinuation
- 2017-04-19 AR ARP170100997A patent/AR108235A1/es unknown
- 2017-04-19 KR KR1020170050614A patent/KR20170119651A/ko unknown
- 2017-04-19 SG SG10201703206TA patent/SG10201703206TA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201703206TA (en) | 2017-11-29 |
| AU2017202534B1 (en) | 2017-06-08 |
| JP2017214352A (ja) | 2017-12-07 |
| KR20170119651A (ko) | 2017-10-27 |
| AR108235A1 (es) | 2018-08-01 |
| ZA201702773B (en) | 2018-11-28 |
| RU2017113518A (ru) | 2018-10-19 |
| CA2964581A1 (en) | 2017-10-19 |
| MY185460A (en) | 2021-05-19 |
| EP3243507A1 (en) | 2017-11-15 |
| CL2017000957A1 (es) | 2017-12-15 |
| CA2964581C (en) | 2020-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018003331A (es) | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. | |
| PH12017502079A1 (en) | Treatment of beta-thalassemia using actrii ligand traps | |
| MX2021005561A (es) | Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco. | |
| NZ732154A (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| BR112017017078A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença. | |
| MX2019002212A (es) | Compuestos de amino-pirrolo-pirimidinona y metodos de uso de los mismos. | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| PH12016500164A1 (en) | Therapeutically active compounds and their methods of use | |
| MY192055A (en) | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation | |
| MY176246A (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease | |
| EA201691789A1 (ru) | Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты | |
| NZ751969A (en) | Dosage regimen for a controlled-release pth compound | |
| PH12019500177A1 (en) | Treatment and prevention of sleep disorders | |
| PH12017500029A1 (en) | 4,5-dihydroisoxazole derivatives as nampt inhibitors | |
| EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
| PH12017500007A1 (en) | Quinolizinone derivatives as p13k inhibitors | |
| MY190972A (en) | Pharmaceutical composition for treating cancer, containing lactate metal salt | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| MY179783A (en) | Substituted bicyclic compounds | |
| EA035519B9 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
| MX2017005042A (es) | Formas de dosificacion oral de magnesio de liberacion controlada, de alta carga y metodos para elaborar y utilizar las mismas. | |
| MX2022007315A (es) | Formulaciones de olanzapina de liberacion sostenida. | |
| MX2018004532A (es) | Combinacion de trazodona y gabapentina para el tratamiento de dolor. | |
| MX2019006593A (es) | Compuestos de acido ascorbico y quinona para el tratamiento de la enfermedad de chagas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |